Business Context and Reporting Period
This Form 6-K filing by BioLineRx Ltd. covers the month of August 2026, with the report dated August 28, 2026. The filing primarily announces a registered direct offering and a concurrent private placement, details of which are contained in the press release filed as Exhibit 1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital raising activities rather than operational financial performance.
Material Changes
- Capital Raising: The Company announced a registered direct offering and concurrent private placement.
- ATM Facility Adjustment: Concurrent with the new offering, the Company reduced the maximum aggregate offering amount of its existing At-the-Market (ATM) Facility to zero. Previously, the ATM Facility, governed by an agreement with H.C. Wainwright & Co., LLC, had a maximum aggregate offering amount of $4,870,000 as of the prospectus supplement filed on July 25, 2025.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary on future operational guidance, risks, contingencies, or unusual items beyond the disclosure of the capital raising transaction. The press release incorporated by reference (Exhibit 1) would contain further details on the terms of the offering.
Investor Verification Checklist
- Verify the specific terms, price, and total proceeds of the registered direct offering and concurrent private placement in Exhibit 1.
- Confirm the impact of the ATM Facility reduction to zero on the Company's future ability to raise capital through that specific channel.
- Review the use of proceeds disclosed in the accompanying press release.